This post was originally published on this site
The move comes as advisors to the U.S. Food and Drug Administration meet to review the potential traditional approval of an Alzheimer’s disease drug made by the biotech company and partner Eisai.
On Wednesday, data from a late-stage trial released by the FDA showed that the treatment, known as Leqembi, helped stem the progression of cognitive decline in patients suffering from Alzheimer’s disease.
The documents also suggested that safety worries would most likely not hurt the chances that the drug will be given the green light from regulators.
The FDA is expected to deliver a formal decision by July 6.
